| abstract |
The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: n nor a pharmaceutically acceptable salt thereof, wherein Ring A, X, R 1 , R 2 and n are as defined and described herein, in a method for promoting wound healing in a subject. |